GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (NAS:IRWD) » Definitions » Operating Margin %
中文

Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Operating Margin %

: 36.76% (As of Dec. 2023)
View and export this data going back to 2010. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Ironwood Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $43.2 Mil. Ironwood Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $117.6 Mil. Therefore, Ironwood Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was 36.76%.

The historical rank and industry rank for Ironwood Pharmaceuticals's Operating Margin % or its related term are showing as below:

IRWD' s Operating Margin % Range Over the Past 10 Years
Min: -195.04   Med: 11.5   Max: 60.97
Current: 38.02


IRWD's Operating Margin % is ranked better than
97.55% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 6.34 vs IRWD: 38.02

Ironwood Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Ironwood Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $43.2 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $168.3 Mil.


Ironwood Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Ironwood Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ironwood Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.32 40.65 56.12 60.97 38.02

Ironwood Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.77 57.75 18.92 39.31 36.76

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ironwood Pharmaceuticals Operating Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Ironwood Pharmaceuticals's Operating Margin % falls into.



Ironwood Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Ironwood Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=168.336 / 442.735
=38.02 %

Ironwood Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=43.21 / 117.553
=36.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ironwood Pharmaceuticals  (NAS:IRWD) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Ironwood Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Executives
Marla L Kessler director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Andrew Davis officer: SVP, Chief Business Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sravan Kumar Emany officer: SVP, Chief Financial Officer 100 SUMMER ST, SUITE 2300, BOSTON MA 02109
Ronald Silver officer: Principal Accounting Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Minardo John officer: Chief Legal Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Thomas A Mccourt officer: Chief Commercial Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Michael Shetzline officer: CMO,SVP,Head-Res&Drug 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jason Rickard officer: SVP, Chief Operating Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark G Currie officer: Chief Scientific Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Edward P Owens director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gina Consylman officer: Chief Accounting Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Kilroy Conor officer: SVP, GC & Secretary 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110

Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Headlines

From GuruFocus